Connect with us

Healthcare

Cannabis Users are Less Likely to Get Liver Cancer Says New Medical Study

Published

on

Liver cancer is one of the fastest-growing cancers. Once you have it, liver cancer is a life-threatening condition and it can quickly turn fatal.

Primary liver cancer begins in the organ itself, while secondary cancer means that it has spread to the liver from another part of the body.  Among the three kinds of primary liver cancer, hepatocellular carcinoma (HCC) is the most common form, followed by intrahepatic cancer then angiosarcoma. Liver cancer can be caused by several factors including fatty liver disease, diabetes, alcoholism, tobacco smoking, obesity, and toxic chemical exposure.

Though liver cancer mostly affects seniors aged 55 to 65, anyone can get liver cancer.  The prognosis is 3 to 35, according to Cancer.org, depending on how far the cancer has progressed once it has been diagnosed.

However, new studies have shown that cannabis consumers are less likely to get liver cancer.

New data that has been published in Cureus, a medical journal, revealed that adults who have a recent history of marijuana consumption are twice less likely to develop hepatocellular carcinoma compared to those who don’t have a history of cannabis use. To come up with these findings, researchers from Cleveland Clinic together with investigators at the Georgetown University Hospital in Washington DC analyzed more than 1 million subjects as well as their cannabis consumption patterns and the prevalence of hepatocellular carcinoma among them.


They reported that current marijuana consumers are “55 percent less likely to have HCC compared to non-cannabis users.”

“To the best of our knowledge, this is the first and largest population-based cross-sectional study of hospitalized patients to explore the association between cannabis use and HCC…. Due to the cross-sectional structure of our study, we are unable to draw direct causation effects. Hence, we suggest prospective clinical studies to further understand the mechanism by which various active ingredients, particularly CBD in cannabis, may possibly regulate hepatocellular carcinoma development,” the authors concluded.

Other Studies

There have been other studies that echo these findings.

In 2018, a study analyzed around 320,000 participants all of whom had a history of alcohol abuse as well as marijuana. The researchers wanted to see if there was any correlation between alcohol and drugs on liver health. According to Dr. Terence Bukong, one of the study’s researchers: “The primary aim of our study was to assess the impact of cannabis use and the development of alcoholic liver disease,” he tells Healthline. “Given that no clinical studies had previously evaluated the impact of cannabis use and the development of progressive stages of alcoholic liver disease in humans, we thought that this was an important research area which needed urgent investigation,” he says.

Meanwhile, a study out of the Hebrew University of Jerusalem discovered a way of treating liver cancer patients with chemotherapy straight into the affected cells while keeping the healthy cells intact. The method makes use of CBD together with a low dose of doxorubicin, a medicine commonly used in chemotherapy.

“Most anticancer treatments are not sufficiently specific, meaning they attack healthy cells together with the malignant ones they’re trying to get rid of,” says Prof. Alexander Binshtok, the Hebrew University’s Faculty of Medicine and Edmond & Lily Safra Center for Brain Sciences head for Pain Plasticity Research. “This leads to many serious side effects associated with chemotherapy. Eliminating cancerous cells while leaving healthy ones alone is an important step toward reducing patients’ suffering,” he adds.

Doxorubicin works for the cancerous cells, though it also has negative side effects for liver and heart cells, which can even cause heart failure when used for liver cancer treatment, Binshtok told The Jerusalem Post.

Another study from 2020 shared similar findings – that cannabis users are generally less likely to contract cancer, compared to non-users.

A meta review conducted by Indiana University South Bend Departmental Chair & Professor of Biology, Dr. Thomas M. Clark, involved 34 varying research studies on marijuana and cancer. Using a statistical analysis, he was able to discover that cannabis users are generally healthier and had a smaller chance of getting cancer.

“The impact of cannabis use on cancer risk is of considerable interest,” Clark said. “Cancer is a leading cause of death in the United States and around the world. In the United States alone, >1.7 million diagnoses and 607,000 deaths are projected from cancer in 2019…. And cancer deaths were responsible for $94.4 billion in lost earnings in 2015,” he says.

The statistical analysis took all kinds of cancer into account, and they ended up concluding that cannabis use may actually decrease the risk for cancer by 10%. “Decreased cancer risk in cannabis users should not be surprising, as cannabis and cannabinoids decrease obesity, inhibit chronic inflammation, reduce fasting insulin levels and insulin sensitivity, and have direct antitumor actions,” Clark writes.

Conclusion

Cannabis is simply much more effective than pharmaceutical drugs because the compounds in the plant bind to our very own endocannabinoid system to provide holistic healing. Using cannabis as part of a healthy lifestyle not only aids in reducing stress and anxiety or helping us sleep better, but it also has long-term health benefits. Provided that one also lives a balanced lifestyle, exercises regularly, eats well, and avoids stress, the studies we have so far suggest that adding cannabis to your daily routine can help ward off deadly diseases such as cancer.

Source: https://cannabis.net/blog/medical/cannabis-users-are-less-likely-to-get-liver-cancer-says-new-medical-study

Cannabis & Policy

Supreme Court Raises Concern Over Steep Medicine Mark-Ups at Corporate Hospitals

Published

on

By

The Supreme Court of India has questioned the sharp difference between the prices at which medicines reach retailers and the maximum retail prices charged to patients, particularly in corporate hospitals.

During a hearing on September 29, a bench of Justices Vikram Nath and Sandeep Mehta examined whether a uniform limit of 16% could be applied to medicine margins. The discussion followed the court’s earlier concern over a cancer medicine with a retailer price of about ₹2,700–₹3,000 but an MRP of ₹27,000.

Court Questions Wide Gap Between Retail Price and MRP

The Supreme Court focused on how such large differences between the Price to Retailer (PTR) and MRP can affect patients who have little choice over where they obtain medicines during hospital treatment.

The bench questioned why different pricing rules should apply to essential and non-essential medicines and asked whether a common 16% margin could be considered across pharmaceutical products. The issue remains under consideration and the court has not imposed such a cap at this stage.

Concerns Over In-House Hospital Pharmacies

The court also examined the purchasing practices of corporate hospitals.

According to the proceedings, patients admitted to some hospitals may be directed to obtain medicines from the facility’s own pharmacy. The bench raised concerns about situations in which hospitals may not accept medicines purchased from outside pharmacies or may decline to provide treatment assurances when patients bring their own drugs.

The issue becomes particularly significant for patients undergoing expensive or long-term treatments, where medicine costs can represent a substantial part of the overall bill.

Impact on Government Health Schemes

The Supreme Court also highlighted the potential effect of high medicine prices on publicly funded healthcare programmes.

Where treatment is reimbursed under government schemes, the court noted that taxpayers ultimately finance the medical expenses. If reimbursement is calculated using substantially inflated MRPs, the difference between procurement costs and the amount reimbursed could increase public expenditure.

The bench also pointed to a consumer-trust problem. If a medicine officially carries an MRP of ₹27,000 but a pharmacy offers it for around ₹3,000, patients may question whether the cheaper medicine is genuine.

Government Seeks Time to Examine the Issue

Solicitor General Tushar Mehta, appearing for the Centre, told the court that the government would need to work out a balanced approach.

The government has been asked to examine the issue with relevant officials before responding further. The court granted additional time for consultations rather than immediately introducing a new pricing rule.

The proceedings are part of a broader case concerning medicine pricing, generic prescriptions and regulation of medical costs. The Supreme Court’s official website lists Justice Vikram Nath and Justice Sandeep Mehta as sitting together in Court No. 2 on September 29, 2026.

Court’s Earlier Warning on Medicine Pricing

The latest hearing follows strong observations made by the Supreme Court earlier in September after it examined the pricing of cancer medicines.

The bench had highlighted an example where a medicine costing roughly ₹2,700 at the retailer level carried an MRP of ₹27,000. The court questioned how such a substantial price difference could be justified when patients are dependent on life-saving medicines.

The court also heard arguments that pharmaceutical manufacturers may not necessarily retain the entire difference between the retailer price and the final amount charged to patients, with significant margins potentially arising at later stages of the supply chain, including retail and hospital sales.

What Happens Next?

The Supreme Court has not yet ordered a nationwide 16% medicine-margin cap. Instead, it has asked the government to consider possible regulatory solutions and return with its response.

The matter is scheduled for further hearing on October 12, when the court is expected to consider the government’s position on medicine pricing and related issues.

Any eventual regulatory change could have implications for patients, hospitals, pharmacies, pharmaceutical companies and government-funded healthcare programmes. For now, the 16% figure remains a proposal raised during the court proceedings rather than an operative rule.

Continue Reading

Economic Fraud

Fugitive Medicare Fraud Suspect Returned to US After Arrest in Türkiye

Published

on

By

U.S. federal authorities have secured the return of a fugitive suspect accused of involvement in a massive Medicare fraud operation, following his arrest in Türkiye. The extradition marks a significant development in a major healthcare fraud investigation that allegedly cost the American healthcare system billions of dollars.

The suspect, Ibrahim Khaldoon Hilmi, is now in federal custody after spending more than a year outside the United States. Prosecutors are expected to move forward with criminal proceedings as investigators continue to examine what authorities describe as a sophisticated fraud network targeting public healthcare funds.

International Manhunt Ends with Arrest in Türkiye

According to federal investigators, Hilmi left the United States in May 2025 while authorities were building their case. Law enforcement agencies later tracked his location to Türkiye, where cooperation between U.S. and Turkish officials led to his detention.

Following the completion of legal and diplomatic procedures, the suspect was transferred to American custody. Officials described the operation as a successful example of international law enforcement collaboration in pursuing suspects accused of large-scale financial crimes.

A specialized FBI team reportedly traveled to Türkiye to coordinate the transfer and ensure the extradition process was completed smoothly.

Alleged Scheme Targeted Medicare Reimbursement System

Investigators allege that Hilmi played a central role in a fraudulent operation that exploited the Medicare reimbursement system through false claims and improper billing practices.

Authorities estimate that the alleged scheme involved financial losses equivalent to approximately ₹31,700 crore, making it one of the most significant healthcare fraud investigations in recent years.

While the allegations have yet to be tested in court, investigators believe the operation relied on complex financial transactions and coordinated activities designed to extract funds from a government healthcare program serving millions of beneficiaries.

Federal Agencies Expand Investigation

The case extends beyond a single suspect. Federal authorities are examining the potential involvement of additional individuals, businesses, and organizations believed to be connected to the alleged fraud network.

Investigators are reviewing banking records, financial transactions, corporate structures, and digital evidence to determine the full scope of the operation and identify any additional participants.

Officials indicated that tracing the movement of funds and uncovering potential links between entities remains a key focus of the ongoing investigation.

Healthcare Fraud Remains a Major Concern

Government agencies continue to treat Medicare fraud as a serious threat because it impacts taxpayer-funded healthcare resources intended for legitimate medical services.

Authorities argue that fraudulent claims can divert critical funding, increase administrative costs, and place additional pressure on public healthcare programs. As healthcare systems become increasingly digitized, fraud schemes have also become more sophisticated and difficult to detect.

Financial crime specialists note that modern healthcare fraud investigations often involve shell companies, layered transactions, and cross-border financial networks that require extensive forensic analysis.

Growing Importance of Global Law Enforcement Cooperation

The successful return of Hilmi highlights the increasing role of international cooperation in combating financial crime. Law enforcement agencies worldwide are relying more heavily on cross-border partnerships to locate and apprehend suspects who attempt to evade prosecution by relocating overseas.

Officials say such collaborations are essential as financial crimes become increasingly global in nature, involving multiple jurisdictions and complex international money flows.

Legal Proceedings Ahead

The U.S. Department of Justice is expected to present evidence against the suspect as court proceedings move forward. Prosecutors will seek to establish the extent of the alleged fraud and determine accountability among those involved.

The outcome of the case could influence future enforcement efforts aimed at protecting public healthcare programs and strengthening safeguards against large-scale financial misconduct.

For federal authorities, the extradition of Ibrahim Khaldoon Hilmi represents a major step in an ongoing campaign to crack down on healthcare fraud and recover public funds allegedly lost through criminal schemes.

Continue Reading

Cyber Crime

Telangana Doctors Lose Nearly ₹30 Crore to Cyber Fraud Since September 2024

Published

on

By

Cybercriminals have defrauded doctors across Telangana of nearly ₹30 crore since September 2024, prompting authorities to strengthen awareness campaigns and cybersecurity education within the healthcare sector.

The alarming figures were revealed during a cyber awareness programme organized by the Telangana Cyber Security Bureau (TGCSB) in Hyderabad. Senior officials warned that healthcare professionals are increasingly becoming targets of sophisticated online scams despite their educational and professional backgrounds.

Healthcare Professionals Under Growing Cyber Threat

Addressing representatives from various medical associations, TGCSB Director Shikha Goel highlighted the rising number of cybercrime incidents involving doctors and healthcare workers. She emphasized that cybercriminals are exploiting digital platforms to target individuals across all professions, including highly qualified medical practitioners.

Officials stressed that vigilance, awareness, and prompt reporting remain the strongest defenses against cyber fraud. The event focused on strengthening cooperation between law enforcement agencies and the medical fraternity to improve preparedness against evolving cyber threats.

More than 70 office-bearers from medical organizations across Telangana attended the session, including presidents, secretaries, treasurers, and senior representatives.

Investment Scams Responsible for Major Financial Losses

According to TGCSB data, at least 735 doctors have reported cybercrime-related incidents since September 2024, with total losses reaching approximately ₹29.88 crore.

Business and investment fraud emerged as the most damaging category, accounting for losses of ₹22.39 crore involving 127 victims. Investigators noted that fraudsters often lure professionals with promises of high returns, fake investment opportunities, and deceptive business schemes.

Authorities also reported a wide range of other cyber offences affecting doctors, including digital arrest scams, identity theft, impersonation fraud, fake advertisements, job-related scams, insurance fraud, cryptocurrency fraud, UPI-related cheating, matrimonial scams, and sextortion cases.

Authorities Stress Importance of Rapid Reporting

The Telangana Cyber Security Bureau urged victims to report cybercrime incidents immediately, especially during the critical “golden hour” after a fraudulent transaction occurs.

Officials explained that timely complaints through the national cybercrime helpline 1930 and the official cybercrime reporting portal can significantly improve the chances of freezing suspicious transactions and recovering stolen funds.

The bureau further warned that cybercriminals are employing increasingly advanced techniques to deceive victims, making awareness and quick action more important than ever.

Medical Associations Join Awareness Drive

Representatives from associations of paediatricians, cardiologists, dentists, orthopaedic surgeons, gynaecologists, and hospital administrators participated in the discussions. The groups pledged to work closely with authorities to spread cybersecurity awareness through hospitals, clinics, medical conferences, and professional training programmes.

Officials believe that expanding cyber awareness among healthcare professionals will play a key role in reducing financial fraud and strengthening digital security across the state’s medical community.

As cyber threats continue to evolve, law enforcement agencies are encouraging doctors and other professionals to remain cautious when responding to investment offers, unknown communications, and requests for sensitive financial information online.

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News